Biology42
开放对外授权
适应症
II期临床
I期临床
IND-enabling
先导化合物
优化
优化
Hit-to-lead
靶点发现
另有20+创新项目处于药物发现阶段
Medicine42
Science42
Large Language of Life Models (LLLMs)
LLM Assistant
生成式人工智能软件驱动药物研发、
科学研究和可持续发展
科学研究和可持续发展
生成式AI和机器人技术驱动发现的
高质量药物管线
高质量药物管线
想了解更多有关Pharma.AI的信息吗？
Generative AI and Robotics
for Longevity and Sustainability
for Longevity and Sustainability
英矽智能如何从早期蛋白质建模到达AI 赋能药物研发
在这个讲座中，Levitt 博士介绍了 50 年以来计算机速度的大幅提升和机器学习的惊人进步如何提升和帮助了他的研究。他谈到了 OPUS-X 和 AlphaFold，以及相关技术贡献对人类能力和认识的提高。
Levitt 博士表示，英矽智能正在创建从头开始由人工智能驱动的创新药物发现解决方案。以识别疾病出发，训练人工智能做它最擅长的事情——分析从许多组件中获得的大量数据，从而发现潜在的靶点并从头设计新分子。
Levitt 博士表示，英矽智能正在创建从头开始由人工智能驱动的创新药物发现解决方案。以识别疾病出发，训练人工智能做它最擅长的事情——分析从许多组件中获得的大量数据，从而发现潜在的靶点并从头设计新分子。
Most innovative biotechnology company in the world 2024
TNIK
TNIK Inhibitor: Treating Fibrotic diseases of the Lung and Kidney
USP1
Ubiquitin Specific Protease 1 (USP1) Inhibitor for the treatment of BRCA-mutant cancer
QPCTL
Glutaminyl-peptide cyclotransferase-like protein (QPCTL) Inhibitor: Novel cancer immunotherapy for COLD tumors
PHD
Proline Hydroxylase (PHD) Inhibitors: Treatment of Inflammatory Bowel Disease (IBD) and Chronic Kidney Disease (CKD)
MAT2A
Methionine adenosyltransferase 2α (MAT2A) Inhibitor: Treatment of MTAP Deficient Cancer
TEAD
Pan-TEAD Inhibitor: Treating Mesothelioma, and Solid Tumors
ENPP1
Ectonucleotide phosphodiesterase 1 (ENPP1) Inhibitor: Treating anti-PD-1/-L1 resistant cancers
KAT6
KAT6 Inhibitor: Treatment of ER+/HER2- Breast Cancer
DGKA
Diacylglycerol kinase A (DGKA) Inhibitor: Treating solid tumors in combination with checkpoint inhibitor
CDK12
Cyclin-dependent kinase 12 (CDK12) Inhibitor: Treating Tumors by Induction of BRCAness
FGFR2/3
FGFR2/3 Dual Inhibitor: Treatment of Solid Tumors
KIF18A
KIF18A Inhibitor: Treating chromosomally unstable cancers with TP53 mutations
3CLPro
Orally Available covalent irreversible 3CLPro Inhibitor for the Treatment of COVID-19 and Coronavirus infection